Gan Li Pharmaceuticals competes on recombinant insulin markets

The company, which has just started clinical phase III in the USA on glargine, in 2015 ranked 3d in the Chinese insulin market, with 11.2%, behind 53.1% of Nordisk and 26.7% of Sanofi, but has overtaken Eli Lilly (9%). Prices offered by Gan Li are about 20 % under those of competitors.

Source: China Bio news release, February 7, 2018

Request a quote for deeper information from

© 2018 Window to China - Bio 4 Business - Imprint